Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cartesian Therapeutics ( (RNAC) ) has shared an update.
On January 9, 2026, Cartesian Therapeutics reported recent progress and its 2026 outlook, highlighting strong Phase 2b data for Descartes-08 in myasthenia gravis, where deep and durable responses were observed through 12 months after a single outpatient course of therapy. The company has initiated the Phase 3 AURORA trial in MG, targeting a more than $1 billion market opportunity, and is planning expansion of Descartes-08 into myositis while citing a strong efficacy signal from a Phase 2 trial in systemic lupus erythematosus that supports broader autoimmune applicability. Cartesian also noted it began a Phase 1/2 pediatric HELIOS trial in children and young adults with autoimmune diseases, including juvenile dermatomyositis, and ended the third quarter of 2025 with about $145 million in cash, which it expects will fund planned operations, including completion of the Phase 3 MG trial, into mid-2027.
The most recent analyst rating on (RNAC) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative gross margin, and negative equity) and bearish technicals (price below key moving averages and negative MACD). Positive corporate updates (encouraging clinical data and a finance leadership hire) provide some offset, but valuation metrics offer limited support due to a non-meaningful negative P/E and no dividend yield.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Cartesian Therapeutics is a late-stage clinical biotechnology company pioneering mRNA-based cell therapies for autoimmune diseases. Its lead investigational product, Descartes-08, is an autologous mRNA CAR-T therapy designed for outpatient administration without lymphodepleting chemotherapy, targeting conditions such as myasthenia gravis, systemic lupus erythematosus and myositis, supported by U.S.-based in-house manufacturing aimed at biologic-like margins and full supply chain control.
Average Trading Volume: 178,712
Technical Sentiment Signal: Sell
Current Market Cap: $201.8M
Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.